Citius Pharmaceuticals Inc. Common
Follow $CTXR
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $CTXR by emailVeridion Score
BETAMEDIUM CONF · 5 of 6 factors measuredsnapshot unavailable for CTXR. Cause unavailable.
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is CTXR moving today?
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
CTXR overview
Related filings and maps
Congress activity in CTXR
No receipt-qualified filings found.
CTXR contract awards, year to date.
Public federal awards linked to this ticker.
CTXR lobbying filings, year to date.
Registered lobbying filings matched to Citius Pharmaceuticals Inc. Common.